A stem cell trial in the United Kingdom has just received funding to initiate a phase II trial. This study will treat relapsing-remitting patients with autologous, mesenchymal stem cells administered intravenously. This study is similar to the MSRCNY stem cell proposal, except that, in the MSRCNY planned trial, we will be using neural progenitor cells which are derived from mesenchymal stem cells  and the cells would be administered intrathecally (directly into the spinal fluid). We eagerly await the progress of this trial and hope to utilize the data in our future applications with the FDA.